Terms: = Ovarian cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Clinical Outcome
7 results:
1. KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in ovarian cancer.
Liu H; Lin J; Zhou W; Moses R; Dai Z; Kossenkov AV; Drapkin R; Bitler BG; Karakashev S; Zhang R
Cancer Immunol Res; 2022 Aug; 10(8):1028-1038. PubMed ID: 35726891
[TBL] [Abstract] [Full Text] [Related]
2. SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition.
Sundararajan V; Tan M; Tan TZ; Ye J; Thiery JP; Huang RY
Sci Rep; 2019 Jun; 9(1):8295. PubMed ID: 31165775
[TBL] [Abstract] [Full Text] [Related]
3. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas.
Zang X; Sullivan PS; Soslow RA; Waitz R; Reuter VE; Wilton A; Thaler HT; Arul M; Slovin SF; Wei J; Spriggs DR; Dupont J; Allison JP
Mod Pathol; 2010 Aug; 23(8):1104-12. PubMed ID: 20495537
[TBL] [Abstract] [Full Text] [Related]
4. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
Wei Y; Xia W; Zhang Z; Liu J; Wang H; Adsay NV; Albarracin C; Yu D; Abbruzzese JL; Mills GB; Bast RC; Hortobagyi GN; Hung MC
Mol Carcinog; 2008 Sep; 47(9):701-6. PubMed ID: 18176935
[TBL] [Abstract] [Full Text] [Related]
5. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
[TBL] [Abstract] [Full Text] [Related]
6. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors.
Barbieri F; Cagnoli M; Ragni N; Foglia G; Bruzzo C; PedullĂ F; Alama A
Clin Cancer Res; 1999 Jul; 5(7):1837-42. PubMed ID: 10430089
[TBL] [Abstract] [Full Text] [Related]
7. nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters.
Scambia G; Ferrandina G; Marone M; Benedetti Panici P; Giannitelli C; Piantelli M; Leone A; Mancuso S
J Clin Oncol; 1996 Feb; 14(2):334-42. PubMed ID: 8636741
[TBL] [Abstract] [Full Text] [Related]